TopAlliance Biosciences

TopAlliance Biosciences pertence à Junshi Biosciences.

Junshi Biosciences é uma das ...

• CSI 500.

Junshi Biosciences é uma empresa listada sob o símbolo 688180 (HK).

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da TopAlliance Biosciences

• Sheng Yao, Chief Executive Officer and Executive Director
• Qian Zhi, Director
• Xinjun Chen, Director

Criar um alerta
para seguir os movimentos de executivos da TopAlliance Biosciences.

Junshi Biosciences possui 2.290 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnologia

• Attovia Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 14 de maio de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado em 13 de maio de 2024).
• Aardvark Therapeutics acaba de anunciar uma arrecadação de fundos de 85 milhões de dólares. (publicado em 12 de maio de 2024).

Outros contatos sugeridos na indústria do Biotecnologia

• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics
• Carl Gordon - Director da Adicet Bio
• Vik Bajaj - Director da Interline Therapeutics

Saiba mais sobre a indústria do Biotecnologia >

Últimos comunicados de imprensa de TopAlliance Biosciences

• Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
• Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 | Eli Lilly and Company
• Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies
• Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia
• Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
• Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients
• Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study
• Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
• Junshi Biosciences Announces Approval for Marketing of VV116 in China
• Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
• View more press releases Close

Redes sociais sobre TopAlliance Biosciences

• TopAlliance Biosciences na Wikipedia, Google News e Yahoo Finance
• TopAlliance Biosciences na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Sheng Yao

Ligue para a TopAlliance Biosciences em +86 212...

Veja o organograma

Register to receive your alert

Relatório um erro